Key result
Cardiac amyloidosis linked to highly underestimated arrhythmia and conduction risks with unclear optimal pacemaker timing.
Why the study?
Arrhythmias and conduction disorders in cardiac amyloidosis are frequent and underestimated, the timing of pacemaker implantation remains unclear, and commonly used drugs may be poorly tolerated.
Highlights the high burden of arrhythmias in cardiac amyloidosis and the clinical challenges regarding pacemaker timing and drug tolerance.
Supports heightened arrhythmia surveillance in cardiac amyloidosis; leaves open optimal pacemaker timing and drug tolerance.
<ns3:p>Cardiac amyloidosis is characterized by the extracellular deposition of fibrillar proteins in various heart parts, which can lead to restrictive heart failure and cardiac arrhythmias. In many cases, the incidence of both atrial and ventricular arrhythmias and conduction disorders is high and underestimated. The clinical picture often manifests itself only at the time of extensive involvement of the muscular and conduction system of the heart. Secondary to amyloid infiltration, bradyarrhythmias, and conduction disorders can occur, however, the timing of pacemaker implantation remains unclear. Many commonly used drugs may be poorly tolerated by patients with cardiac amyloidosis.</ns3:p>
No takes yet. Share an insight, caveat, or question.
Pabis et al. (2023) conducted a review in Cardiac amyloidosis. Cardiac amyloidosis is associated with a high and underestimated incidence of atrial and ventricular arrhythmias and conduction disorders, with unclear optimal timing for pacemaker implantation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: